{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T04:05:30Z","timestamp":1749873930776,"version":"3.41.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 33-year-old man with primary intestinal lymphangiectasia (Waldmann disease) associated with PIK3CA-related overgrowth spectrum was explored using <jats:sup>99m<\/jats:sup>Tc serum albumin scintigraphy before and during treatment by alpelisib, a specific PIK3CA inhibitor. Before treatment, scintigraphic images evidenced a focal uptake on the right colonic angle 4\u2009hours postinjection (p.i.), diffusing to the transverse and left colon 24\u2009hours p.i., compatible with a diffuse colonic exudation. Significant scintigraphic improvement was observed with a disappearing of the right colonic angle uptake 4\u2009hours p.i. and later images 14\u2009months after alpelisib introduction.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005680","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T06:00:15Z","timestamp":1739772015000},"page":"527-530","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Scintigraphic Improvement of Primary Intestinal Lymphangiectasia in a Patient Treated With Alpelisib for a PIK3CA-Related Overgrowth Spectrum"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1046-3200","authenticated-orcid":false,"given":"Julien","family":"Dubois","sequence":"first","affiliation":[{"name":"Department of Radiopharmacy, Montpellier University Hospital, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Vauchot","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Montpellier University Hospital, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"bib1-20250613","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1750-1172-3-5","article-title":"Primary intestinal lymphangiectasia (Waldmann\u2019s disease)","volume":"3","author":"Vignes","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"bib2-20250613","first-page":"215","article-title":"99mTc-human serum albumin scans in children with protein-losing enteropathy","volume":"41","author":"Halaby","year":"2000","journal-title":"J Nucl Med"},{"key":"bib3-20250613","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1148\/radiology.219.1.r01ap2986","article-title":"Protein-losing enteropathy: diagnosis with (99m)Tc-labeled human serum albumin scintigraphy","volume":"219","author":"Chiu","year":"2001","journal-title":"Radiology"},{"key":"bib4-20250613","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000327914","article-title":"Evaluation of performance of measurement of faecal \u03b1(1)-antitrypsin clearance and Technetium-99m human serum albumin scintigraphy in protein-losing enteropathy","volume":"84","author":"Chau","year":"2011","journal-title":"Digestion"},{"key":"bib5-20250613","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41395-018-0413-0","article-title":"Primary intestinal lymphangiectasia (Waldmann\u2019s disease)","volume":"114","author":"Borzutzky","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"bib6-20250613","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1097\/RLU.0000000000003285","article-title":"Primary intestinal lymphangiectasia: diagnostic accuracy of 99mTc-labeled human serum albumin nanocolloid SPECT\/CT before biopsy","volume":"46","author":"Pascal","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib8-20250613","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s13023-021-01929-8","article-title":"A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations","volume":"16","author":"Canaud","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"bib9-20250613","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41586-018-0217-9","article-title":"Targeted therapy in patients with PIK3CA-related overgrowth syndrome","volume":"558","author":"Venot","year":"2018","journal-title":"Nature"},{"key":"bib10-20250613","doi-asserted-by":"crossref","first-page":"e20212148","DOI":"10.1084\/jem.20212148","article-title":"Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib","volume":"219","author":"Morin","year":"2022","journal-title":"J Exp Med"},{"key":"bib11-20250613","doi-asserted-by":"crossref","first-page":"100969","DOI":"10.1016\/j.gim.2023.100969","article-title":"Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS)","volume":"25","author":"Canaud","year":"2023","journal-title":"Genet Med"},{"key":"bib12-20250613","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/1078-0432.CCR-23-1270","article-title":"FDA approval summary: alpelisib for PIK3CA-related overgrowth spectrum","volume":"30","author":"Singh","year":"2024","journal-title":"Clin Cancer Res"},{"key":"bib13-20250613","first-page":"590","article-title":"Alpelisib: a novel agent for PIK3CA-related overgrowth spectrum","volume":"28","author":"Nadjkovic","year":"2023","journal-title":"J Pediatr Pharmacol Ther"},{"key":"bib14-20250613","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s005350170142","article-title":"Primary intestinal lymphangiectasia successfully treated with octreotide","volume":"36","author":"Kuroiwa","year":"2001","journal-title":"J Gastroenterol"},{"key":"bib15-20250613","doi-asserted-by":"crossref","first-page":"e20152562","DOI":"10.1542\/peds.2015-2562","article-title":"Everolimus for primary intestinal lymphangiectasia with protein-losing enteropathy","volume":"137","author":"Ozeki","year":"2016","journal-title":"Pediatrics"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T12:00:14Z","timestamp":1749816014000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005680","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"type":"print","value":"0363-9762"},{"type":"electronic","value":"1536-0229"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"2024-08-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}